<DOC>
	<DOCNO>NCT02947945</DOCNO>
	<brief_summary>Reslizumab type medicine call monoclonal antibody make research clinic ; work block specific protein body call interleukin-5 . The study medicine , reslizumab , yet approve doctor treat patient EGPA . It consider experimental drug study .</brief_summary>
	<brief_title>Reslizumab Treatment Eosinophilic Granulomatosis With Polyangiitis ( EGPA ) Study</brief_title>
	<detailed_description>This study open-label mean subject receive study medication . The study medicine - reslizumab - give participant addition medicine already take treat EGPA oral steroid ( e.g . prednisone ) medicine reduce activity immune system ( study doctor tell participant medication ) - meant 'standard care ' vary different country . Drugs sometimes use ( i.e. , 'standard care ' ) reduce activity immune system EGPA ( addition oral steroid ) include azathioprine , methotrexate , mycophenolate mofetil cyclophosphamide . Information study drug affect human body health collect number test , procedure question . The study medicine , reslizumab , give participant dose 3mg/kg intravenously ( within vein ) every four week 28 week total 7 treatment . During treatment phase study , study staff member call participant every two week see , medication take , able decrease steroid use . The study total 11 study visit 44 week time period . Everyone take part study continue receive his/her exist treatment EGPA ( although dose oral steroid may reduce study ) .</detailed_description>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<criteria>Informed Consent : Able give write informed consent prior participation study , include ability comply requirement restriction list consent form . Subjects must able read , comprehend , write level sufficient complete study related material . Gender Age : Male female subject &gt; 18 year old EGPA diagnosis : subject diagnose EGPA least 6 month base history presence : asthma plus eosinophilia ( &gt; 1.0x109/L and/or &gt; 10 % leucocyte ) plus least two follow additional feature EGPA : A biopsy show histopathological evidence eosinophilic vasculitis , perivascular eosinophilic infiltration , eosinophilrich granulomatous inflammation ; Neuropathy , mono poly ( motor deficit nerve conduction abnormality ) ; Pulmonary infiltrates , nonfixed ; Sinonasal abnormality ; Cardiomyopathy ( establish echocardiography MRI ) ; Glomerulonephritis ( haematuria , red cell cast , proteinuria ) ; Alveolar haemorrhage ( bronchoalveolar lavage ) ; Palpable purpura ; ANCA positive ( MPO PR3 ) . Subjects receive cyclophosphamide ( CYC ) induction regimen may include minimum 2 week last dose daily oral CYC , 3 week last dose pulse IV CYC prior visit 1 , total WBC ≥4x109/L prior visit 1 . Subjects receive methotrexate , azathioprine , mycophenolate mofetil induction regimen may include stable dose least 4 week prior visit 1 . Corticosteroid therapy : Subject must stable dose oral prednisolone prednisone ≥5 mg/day least 4 week prior visit 1 . Immunosuppressive therapy : If receive immunosuppressive therapy ( include methotrexate , azathioprine , mycophenolate mofetil , exclude restrict medication ) dosage must stable 4 week prior visit 1 study ( dose reduction safety reason permit ) . Female subject : To eligible entry study , female childbearing potential ( FCBP ) must commit consistent correct use acceptable method birth control begin consent , duration trial . Hypereosinophilic Syndrome Wegener 's Granulomatosis Malignancy Parasitic disease Pregnant nursing If female childbearing potential , must negative pregnancy test must adhere acceptable method contraception ( &lt; 1 % failure rate ) study four month study . Any medical illness precludes study involvement Patients currently receive previously receive reslizumab type antiinterleukin therapy ( i.e . mepolizumab , lebrikizumab etc . ) within last three month . Taking cyclophosphamide Any patient know hypersensitivity reslizumab excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>